Vitiligo
Conditions
Brief summary
The goal of this clinical trial is to learn if topical crisaborole ointment works to treat vitiligo. It will also learn about the safety of the drug. The main questions it aims to answer are: Can the drug cause repigmentation of vitiligo lesions when used as topical form after microneedling? What medical problems do participants have when the drug used? Participants will: Visit the clinic once every 2 weeks to have the microneedling sessions for 3 months. and also they will have narrow band UVB sessions two times per week. Record any side effect they have during or after the sessions.
Interventions
PROCEDUREmicroneedling with topical crisaborole
From each patient 3 patches will be selected The first will have microneedling and topical crisaborole and NB UVB sessions The second will have microneedling and NB UVB sessions The third will be exposed only to NB UVB sessions The microneedling sessions will be every 2 weeks for 6 sessions
Sponsors
Tanta University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients suffer from non-segmental stable vitiligo. * Patients who will accept to be included in the study and will sign a written consent.
Exclusion criteria
* Patients with history of koebnerization or any sign of disease activity. * Patients with keloid tendency. * Patients with active infection. * Pregnant or lactating woman.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Repigmentation of vitiligo lesions | 3 months from the start of treatment | The repigmentation responses will be expressed qualitatively as the following No change (0%-25%) = mild improvement (26%-50%) = moderate improvement (51%-75%) = good improvement (76%-100%) = excellent improvement |
Outcome results
None listed